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Introduction
This case report describes a 42-year-old Caucasian woman who presented with persistent hyperamylasaemia and no evidence of pancreatic pathology. Further investigations resulted in a diagnosis of Iight-chain multiple myeloma. Amylase production by epithelial tumours has been well documented but the association with multiple myeloma has only been described inasmall number ofcases. The link does not appear to be immunoglobulin class-specific but the association with Bence Jones myeloma is unusual. The common features in this group of patients have been extensive extramedullary spread with ahigh tumour mass and a poor prognosis. This case was similar in that the patient showed very rapid disease activity developing extensive metastatic lesions and treatment Ultimately proved unsuccessful. The amylase concentrations have been shown to decrease in response to treatment and increase at times of relapse and it has been proposed that it may be useful as a tumour marker in these patients. This case study adds to the pool ofpatients with this unusual association. 
Case history
The assay of the enzyme serum amylase is in common use as part of the investigation of pancreatic disease. Amylase has been found to be present in a number of organs and tissues. The greatest concentration is found in the pancreas but the salivary glands also produce a potent amylase and the two isoenzymes of amylase are termed accordingly pancreatic (P) and salivary (S). They are the products of two closely linked loci on chromosome I. In the presence of pancreatic disease amylase activity can be elevated but this is not diagnostic as other conditions can result in a raised concentration. 1 The first case of hyperamylasaernla associated with malignancy was described in 1951.2 This was discovered in a patient with lung cancer. Subsequently hyperamylasaemia has been described in a number of epithelial cancers. [1] [2] [3] [4] [5] More unusually. a raised amylase has been found in non-epithelial malignancies including multiple myeloma.v-"
In this case report we describe a patient who presented with hyperamylasaemia and who was found to have multiple myeloma. This report adds to the small number of cases previously described.
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A 42-year-old Caucasian woman was admitted to hospital in July 1998 with abdominal pain associated with nausea and mild vomiting. On examination she was found to be apyrexial with minimal upper abdominal tenderness which was thought to be due to gallbladder disease or a urinary tract infection. Her initial laboratory results were as follows: Hb 10'7 g/dl, 01'7-15,5 g/dl.), total protein 63 giL (60-80 giL). albumin 39 gil (36-52 gil). adjusted serum calcium 2·71 mmol/L (2 ,2-2,6 mmol/L) and a raised serum amylase at 2571 IU/L «200 IU/L). The method used for amylase analysis was the Roche PNP-G7 assay at 37"C on a Beckman Synchron LX-20 analyser. Over the following 2-3 days her symptoms settled and she had a normal abdominal ultrasound examination. Her amylase. however. remained raised (see Fig. I ). Her past medical history included anorexia. depression and irritable bowel syndrome. There was no history of alcohol abuse.
Macroamylase was excluded as a cause of the increased serum amylase by measurement of amylase activity after precipitation with polyethylene glycol. A value of 13% was obtained (normal < 52 ()O. 22 The urine amylase/creatinine clearance ratio was 2·9% (2-5%).1 Ifmacroamylase is present then this ratio will usually be less than 2 %. 1 The patient was allowed home for follow up at the surgical outpatient clinic but was readmitted prior to that appointment generally unwell and vomiting. On readmission initial X-ray data of her upper abdomen showed two sites of calcification and that of her chest showed abnormal appearances of the sixth left rib but no other focal lesions. A computerized tomography scan confirmed this finding. On this occasion her serum amylase was 3142 Ill/L. Urine immunofixation was positive with monoclonal II: light chains present at 5·02 g/L on presentation. Further specimens during her treatment were difficult to obtain due to her general condition and also that her later care was provided from outside the district. There was no evidence of paraproteinaemia with immunoglobulins quantitated as follows: IgG =6·82 giL (6'-15 g/L),
The electrophoresis was reported as showing a generalized decrease in y globulins. Interestingly an initial iliac crest bone marrow biopsy revealed only reactive changes but biopsy of a lump she had developed over a rib showed poorly differentiated plasma cells. The diagnosis of a light-chain multiple myeloma was made.
From September to December 1998 four courses of chemotherapy (idorubicin with dexamethasone) were given and there was a good response with a decrease in her urinary light-chain excretion to 2 ·52 g/L. In addition her serum amylase fell to 965 Ill/L at this time. In June 1999 she had an autologous bone marrow transplant for disease relapse and her serum amylase had once again risen to over 3000 Ill/L (see Fig. 1 ). After the transplant her serum amylase normalized. In January 2000 a further relapse was managed by a bone marrow allograft and interestingly her amylase on this occasion did not rise. Over the next year her general condition deteriorated and she died from sepsis in March 2001. It is interesting that post transplant. the amylase concentrations did not mirror the disease progress.
Isoenzyme analysis using a Randox (colorimetric) kit was undertaken on a specimen pre-transplant (total amylase 832 Ill/L), The concentration of pancreatic isoenzyme was determined at 49 lUlL Ill/L) amounting to 5·9% of the total value. The pancreatic isoenzyme normally accounts for 60°,{, of the total amylase present. 1 The majority of amylase activity was therefore not due to the pancreatic isoenzyme and was presumed to be due to the salivary type. This patient with light chain myeloma showed very rapid disease activity, from presenting with a few lesions to metastatic lesions of skull. chest and spine.
Discussion
The association between malignancy and hyperamylasaemia was first identified 50 years ago. 2 Amylase production by cancer cells has been demonstrated by tissue culture and immunohistochemical techniques. The most common epithelial tumours involved have been lung and ovary. Osteosarcoma was the first non-epithelial tumour associated with hyperamylasaemla.r"
One of the first cases of multiple myeloma and amylase production was described in Japan in 1988. 6 This patient had a A-IgA myeloma with extramedullary spread and died within 18 months of diagnosis. The amylase isoenzyme was the S type and this appears to be the more common isoenzyme associated with tumours. There have been fewer cases described where the pancreatic isoenzyme or a mixed picture has been associated with mallgnanctes.VV" There have been a number of additional cases described where patients with multiple myeloma have had hyperamylasaemia with no evidence of pancreatic pathology'<-" As in epithelial malignancies. the cancer cells would appear to be the site of amylase production as demonstrated by tissue culture and immunohistochemistry in some of these patients. Initial reports were in patients of Japanese descent but cases in people of Caucasian and African-American origin have been published. The common factors between these cases were extensive extramedullary spread with consequent poor prognosis and all were considered to have a high tumour mass. The isoenzyme present in all the cases to date has been the S type. All of the patients have a similar age distribution to that of multiple myeloma but there would appear to be no uniform immunoglobulin class. A review of amylase producing myeloma is outlined in Table 1 (non-English language references have been included as a guide to total numbers of cases -detailed information from these sources was limited to that available in the English abstract). The mean age of this group of patients is 65 years (standard deviation 7 years). There is a predominance of women in this group with a women-to-men ratio of 2:1. The major heavy chain isotype is IgA followed by IgG. with surprisingly two cases of IgD isotype in such a small series of myeloma patients. A-Lightchain isotype is the predominant group with 2:1 AIK ratio. Interestingly. to date there is no case report of IgM paraprotein associated with hyperamylasaemia.
The triggers and methods of production of amylase in the multiple myeloma patients are unknown. In some of the myeloma cells structural alterations on chromosome 1 have been tdentttled.P It has been postulated that radiotherapy is the trigger for these changes as there has been a case where the hyperamylasaemia developed following palliative radiotherapy? However. there is not always a history of radiotherapy in all the patients prior to documenting a raised amylase. The method of amylase secretion would appear to be different in multiple myeloma patients from other malignancies. In many epithelial tumours amylase-containing secretory granules have been found in the cells but no similar finding has been shown in myeloma patients. 3.12 It is important to determine accurately the cause of hyperamylasaemia in myeloma patients. Acute pancreatitis needs to be excluded. This can occur secondary to hypercalcaemia. Although abdominal ultrasound is not the best diagnostic tool for detecting pancreatitis. a normal result is reassuring. The plasma half-life of amylase is around 3-6 h. Therefore an unchanging or persistently elevated amylase concentration can also point to another cause. Some centres measure serum lipase which may be more specific for pancreatic pathology and a normal concentration in the face of a raised amylase would tend to exclude pancreatitis. In our patient this was not performed as there was a negative ultrasound report and her symptoms settled leaving an isolated raised amylase.
The next cause to consider is macroamylasaemia. This results from immunoglobulin binding with amylase (MW 48-60 kDa) and the resulting larger molecule (MW > 200 kDa) is cleared more slowly from the circulation. The concentration of amylase when measured is therefore high but will indicate clinical disease. Patients with heavy chain myeloma have raised immunoglobulins: whether this predisposes to the presence of macroamylase is uncertain. In our patient immune paresis was evident and this may to some extent reduce the possibility of macroamylasaemia. Further evidence against macroamylasaemia was the normal urinary amylase/ Table 1 . Amylase-producing myeloma -a review of cases reported in the literature Source Hata et al. 6 Kanno et al. 7 Proc. 30 th annual meeting Japanese Clinical Hematological SocietyB Wada et al. 9 Tagawa et a/. lO Natazuka et al. 11 Fujii et al. 12 Moriyama et al. 13 Moriyama at al. 13 Delannoy et al. 14 Lopez et al. 15 Hirota et al. 16 Yamakawa et alY Nakajima et al. 18 In our patient the concentration of pancreatic isoenzyme present was 5·9%. In adults there is variation in the composition of serum amylase. Twelve distinct phenotypes of the S type and six of the P type have been described. Approximately 40% of the S type and 60% of the P type is found in adult populations. Column chromatography was not done to confirm actual identity of the 94% remaining amylase activity but it was concluded that the majority of amylase activity was most likely due to the salivary isoenzyme. No analysis for specific amylase production by the tumour cells or cytogenetics was carried out. Tissue culture findings and immunohistochemical techniques have been performed in several cases proving amylase production by the cancer cells. so the lack of this information in this particular case is probably not that important. The cases of multiple myeloma and hyperamylasaemia would appear to have several features of their disease in common. They feature extramedullary spread with a high tumour mass and short survival time. that is less than 3 years (see Table  1 ).In our patient the amylase concentration decreased in response to treatment and increased at times of relapse. This has been described in other cases where the information has been available. It has been suggested that amylase may be useful as a tumour marker in these patients to monitor disease progression and treatment response. This would not have been possible in our patient following bone marrow autograft and in other cases the onset of hyperamylasaemia is variable. although the association would appear to herald rapid disease progression. However. in the literature there is a case of hyperamylasaemia associated with monoclonal gammopathy of undetermined slgnificance.P This Japanese patient had been monitored for 15 years with a stable M-protein concentration and a modestly elevated amylase. Cell culture demonstrated ectopic amylase production by the plasma cells. The hyperamylasaemia in this case would not appear to be a poor prognostic factor although the degree of hyperamylasaemia may be an important factor. A case of extramedullary plasmacytoma has also been shown to have hyperamylasaemia in whom diagnosis of mu ltiple myeloma had been excluded.v' In conclusion the patient described in this case study has clinical features in common with those patients previously reported. This case. by far the youngest described to date. adds to the small number already described and to the best of our knowledge is the first case of a 1\ light chain myeloma with associated hyperamylasaemia. It is important to be aware of the association of hyperamylasaemia and multiple myeloma and as further cases are documented more information may be gathered on the triggers and mechanism of amylase production.
